JP2019513009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513009A5 JP2019513009A5 JP2018545230A JP2018545230A JP2019513009A5 JP 2019513009 A5 JP2019513009 A5 JP 2019513009A5 JP 2018545230 A JP2018545230 A JP 2018545230A JP 2018545230 A JP2018545230 A JP 2018545230A JP 2019513009 A5 JP2019513009 A5 JP 2019513009A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immune cell
- modified immune
- cdr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002865 immune cell Anatomy 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims 1
- 101150064015 FAS gene Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022088103A JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020057 | 2016-02-25 | ||
| EP16020057.2 | 2016-02-25 | ||
| PCT/US2017/019301 WO2017147383A1 (en) | 2016-02-25 | 2017-02-24 | Modified cells for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088103A Division JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513009A JP2019513009A (ja) | 2019-05-23 |
| JP2019513009A5 true JP2019513009A5 (OSRAM) | 2020-04-02 |
| JP7082574B2 JP7082574B2 (ja) | 2022-06-08 |
Family
ID=55446573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544554A Active JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
| JP2018545230A Active JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544554A Active JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11434294B2 (OSRAM) |
| EP (3) | EP4086285A1 (OSRAM) |
| JP (3) | JP7080819B2 (OSRAM) |
| KR (2) | KR20180111870A (OSRAM) |
| CN (3) | CN108884164B (OSRAM) |
| AU (2) | AU2017224843A1 (OSRAM) |
| BR (2) | BR112018067696A2 (OSRAM) |
| CA (2) | CA3014001A1 (OSRAM) |
| ES (1) | ES2903408T3 (OSRAM) |
| RU (2) | RU2018128464A (OSRAM) |
| SG (2) | SG11201807188VA (OSRAM) |
| WO (2) | WO2017144681A1 (OSRAM) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| EP3371208B8 (en) | 2015-11-02 | 2024-10-23 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
| JP7080819B2 (ja) * | 2016-02-25 | 2022-06-06 | セル メディカ スイッツァランド アーゲー | Ｐｄ－ｌ１に対する結合メンバー |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| GB201617714D0 (en) * | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| RS62865B1 (sr) | 2016-12-08 | 2022-02-28 | Immatics Biotechnologies Gmbh | Novi t-ćelijski receptori i imunoterapija u kojoj se koriste |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| CA3047313A1 (en) | 2016-12-16 | 2018-06-21 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| IL268479B2 (en) | 2017-02-21 | 2024-06-01 | Regeneron Pharma | Anti-PD-1 antibodies for the treatment of lung cancer |
| AU2018251898A1 (en) | 2017-04-13 | 2019-10-31 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| EA201992586A1 (ru) | 2017-04-28 | 2020-03-03 | Файв Прайм Терапьютикс, Инк. | Способы лечения с помощью полипептидов внеклеточного домена cd80 |
| KR102752985B1 (ko) | 2017-12-20 | 2025-01-10 | 포세이다 테라퓨틱스, 인크. | Vcar 조성물 및 사용 방법 |
| CN111684061B (zh) * | 2018-01-19 | 2024-07-30 | 美天施生物科技有限两合公司 | 表达嵌合抗原受体的调节性t细胞 |
| CA3089230A1 (en) | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
| CA3095076A1 (en) * | 2018-03-29 | 2019-10-03 | Adagene Inc. | Anti-pd-l1 antibodies and use thereof |
| KR20210015842A (ko) * | 2018-06-04 | 2021-02-10 | 디아테바 에스.알.엘. | 항-cd99 다이아바디 또는 igg 항체 및 그의 용도 |
| EP3810764A2 (en) | 2018-06-21 | 2021-04-28 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| JP7003295B2 (ja) * | 2018-06-29 | 2022-01-20 | ワイ－バイオロジクス・インコーポレイテッド | Ｌａｇ－３に特異的に結合する単クローン抗体及びその用途 |
| SG11202100208VA (en) | 2018-07-09 | 2021-02-25 | Precigen Inc | Fusion constructs and methods of using thereof |
| AU2019354395A1 (en) * | 2018-10-01 | 2021-05-06 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors |
| AU2019359890B2 (en) | 2018-10-17 | 2024-10-24 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US20210369776A1 (en) * | 2018-12-06 | 2021-12-02 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
| US20220144960A1 (en) | 2018-12-26 | 2022-05-12 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| KR20210133225A (ko) * | 2019-01-28 | 2021-11-05 | 사이포스 바이오사이언시스 인코포레이티드 | 부착된 이종 분자를 car-세포의 비천연 nkg2d 수용체에 선택적으로 전달하는 변형된 비천연 nkg2d 리간드 |
| WO2020183131A1 (en) * | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| JP2022527081A (ja) * | 2019-03-26 | 2022-05-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
| CN110402892A (zh) * | 2019-04-30 | 2019-11-05 | 梁廷波 | 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法 |
| CN112079924B (zh) * | 2019-06-12 | 2024-02-06 | 苏州工业园区唯可达生物科技有限公司 | Pd-l1靶向结合剂及其用途 |
| WO2021000017A1 (en) * | 2019-07-02 | 2021-01-07 | Telix International Pty Ltd | Antibodies against caix with reduced affinity for the neonatal fc receptor |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| PH12022551078A1 (en) * | 2019-11-04 | 2024-06-19 | Regeneron Pharma | Combination therapy to treat brain cancer |
| RU2733430C1 (ru) * | 2019-11-19 | 2020-10-01 | Общество с ограниченной ответственностью «Реал Таргет» | Создание конъюгатов gd2-специфичных антител и фрагментов gd2-специфичных антител с препаратами |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| AU2020396896A1 (en) * | 2019-12-02 | 2022-06-09 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-L1 and methods of use thereof |
| WO2021130535A2 (en) * | 2019-12-28 | 2021-07-01 | Shanghai Cell Therapy Group Company Co., Ltd. | Cell expressing immune modulatory molecules and system for expressing immune modulatory molecules |
| EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| AU2021243909B2 (en) * | 2020-03-23 | 2025-04-10 | Curigin Co.,Ltd. | Structure of oncolytic virus comprising bispecific nucleic acid molecule |
| EP4149526A4 (en) * | 2020-05-14 | 2024-08-07 | Virtuoso Binco, Inc. | HUMANIZED CD38 AND ICAM1 ANTIBODIES AND USES THEREOF |
| US20230293691A1 (en) * | 2020-06-11 | 2023-09-21 | Innovative Cellular Therapeutics Holdings, Ltd. | Cell/gene therapies targeting mage-a4 peptide |
| US20230227557A1 (en) * | 2020-06-25 | 2023-07-20 | Promab Biotechnologies, Inc. | Pd-l1-specific antibody and anti-pd-l1-car-t cells |
| WO2022011256A1 (en) | 2020-07-10 | 2022-01-13 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| WO2022098922A1 (en) * | 2020-11-04 | 2022-05-12 | Senti Biosciences, Inc. | Protein payload release |
| CN112375743A (zh) * | 2020-11-20 | 2021-02-19 | 山东省医学科学院附属医院 | 一种分泌型靶向her2抗原的嵌合抗原受体t细胞及其应用 |
| CA3195317A1 (en) * | 2020-11-30 | 2022-06-02 | Fred Hutchinson Cancer Center | Pd-l1 binding peptides and peptide complexes and methods of use thereof |
| CN113234152B (zh) * | 2021-06-03 | 2023-05-02 | 天津科技大学 | 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用 |
| WO2023274387A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
| US20250179196A1 (en) * | 2021-07-30 | 2025-06-05 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
| CN117999364A (zh) | 2021-08-13 | 2024-05-07 | 艾诺奥医药品有限公司 | 用以治疗脑癌的组合疗法 |
| CN118176017A (zh) * | 2021-10-26 | 2024-06-11 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| AU2023213978A1 (en) * | 2022-01-28 | 2024-08-15 | The University Of North Carolina At Chapel Hill | Natural killer t-cells and methods of using the same |
| CN118005806A (zh) * | 2024-02-08 | 2024-05-10 | 北京市眼科研究所 | 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用 |
| CN120518751B (zh) * | 2025-07-23 | 2025-09-19 | 中国人民解放军军事科学院军事医学研究院 | 抗人4型腺病毒特异性纳米抗体lum44及在抗病毒治疗中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| EP1445264B1 (en) | 2001-07-31 | 2011-09-14 | Ono Pharmaceutical Co., Ltd. | Substance specific to pd-1 |
| CN105175535A (zh) | 2002-05-22 | 2015-12-23 | 艾斯巴技术-诺华有限责任公司 | 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法 |
| GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
| CA2947292C (en) | 2006-12-27 | 2019-07-23 | Emory University | Compositions and methods for the treatment of infections and tumors |
| PL2158315T3 (pl) | 2007-06-25 | 2016-10-31 | Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych | |
| AU2009264566B2 (en) | 2008-06-25 | 2014-05-08 | Novartis Ag | Solubility optimization of immunobinders |
| CN102164958A (zh) | 2008-06-25 | 2011-08-24 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
| EP3467101A3 (en) | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
| US20140255363A1 (en) | 2011-09-16 | 2014-09-11 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR102410078B1 (ko) * | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| MY175869A (en) | 2013-02-26 | 2020-07-14 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| WO2014206561A1 (en) | 2013-06-26 | 2014-12-31 | Numab Ag | Novel antibody frameworks |
| WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
| EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| EP4166148A1 (en) * | 2014-06-06 | 2023-04-19 | Memorial Sloan-Kettering Cancer Center | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| RU2715038C2 (ru) * | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| WO2016034666A1 (en) | 2014-09-04 | 2016-03-10 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| WO2016049459A1 (en) | 2014-09-26 | 2016-03-31 | Baylor College Of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
| CA2965521A1 (en) | 2014-10-31 | 2016-05-06 | Baylor College Of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| CN108064252A (zh) | 2014-12-19 | 2018-05-22 | 达纳－法伯癌症研究所公司 | 嵌合抗原受体及其使用方法 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| JP7080819B2 (ja) * | 2016-02-25 | 2022-06-06 | セル メディカ スイッツァランド アーゲー | Ｐｄ－ｌ１に対する結合メンバー |
-
2017
- 2017-02-24 JP JP2018544554A patent/JP7080819B2/ja active Active
- 2017-02-24 US US16/079,210 patent/US11434294B2/en active Active
- 2017-02-24 RU RU2018128464A patent/RU2018128464A/ru not_active Application Discontinuation
- 2017-02-24 AU AU2017224843A patent/AU2017224843A1/en not_active Abandoned
- 2017-02-24 RU RU2018128462A patent/RU2018128462A/ru not_active Application Discontinuation
- 2017-02-24 BR BR112018067696A patent/BR112018067696A2/pt not_active Application Discontinuation
- 2017-02-24 CA CA3014001A patent/CA3014001A1/en active Pending
- 2017-02-24 CA CA3014067A patent/CA3014067A1/en active Pending
- 2017-02-24 US US16/079,202 patent/US20190048085A1/en not_active Abandoned
- 2017-02-24 AU AU2017223846A patent/AU2017223846A1/en not_active Abandoned
- 2017-02-24 WO PCT/EP2017/054367 patent/WO2017144681A1/en not_active Ceased
- 2017-02-24 EP EP21209739.8A patent/EP4086285A1/en not_active Withdrawn
- 2017-02-24 EP EP17711573.0A patent/EP3420001B1/en active Active
- 2017-02-24 SG SG11201807188VA patent/SG11201807188VA/en unknown
- 2017-02-24 KR KR1020187024673A patent/KR20180111870A/ko not_active Ceased
- 2017-02-24 BR BR112018067698A patent/BR112018067698A2/pt not_active Application Discontinuation
- 2017-02-24 ES ES17711573T patent/ES2903408T3/es active Active
- 2017-02-24 CN CN201780012682.XA patent/CN108884164B/zh not_active Expired - Fee Related
- 2017-02-24 CN CN202211150762.0A patent/CN116082505A/zh active Pending
- 2017-02-24 CN CN201780012727.3A patent/CN108699153B/zh not_active Expired - Fee Related
- 2017-02-24 KR KR1020187027644A patent/KR20190003938A/ko not_active Ceased
- 2017-02-24 EP EP17710091.4A patent/EP3420000A1/en not_active Withdrawn
- 2017-02-24 SG SG11201807187XA patent/SG11201807187XA/en unknown
- 2017-02-24 JP JP2018545230A patent/JP7082574B2/ja active Active
- 2017-02-24 WO PCT/US2017/019301 patent/WO2017147383A1/en not_active Ceased
-
2022
- 2022-05-30 JP JP2022088103A patent/JP2022116230A/ja active Pending
- 2022-08-30 US US17/823,355 patent/US20230235061A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513009A5 (OSRAM) | ||
| JP2019525738A5 (OSRAM) | ||
| JP2019515646A5 (OSRAM) | ||
| IL299221A (en) | CD3 binding antibodies | |
| JP2020530289A5 (OSRAM) | ||
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| JP2018520657A5 (OSRAM) | ||
| IL263542B1 (en) | Bispecific antibodies inhibit immunological checkpoint | |
| JP2022111148A5 (OSRAM) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2019513370A5 (OSRAM) | ||
| JP2019510733A5 (OSRAM) | ||
| JP2017504578A5 (OSRAM) | ||
| JP2020508655A5 (OSRAM) | ||
| JP2019513725A5 (OSRAM) | ||
| JP2017522893A5 (OSRAM) | ||
| IL273402B1 (en) | Anti-hla-a2 antibodies and methods of using the same | |
| JP2020524000A5 (OSRAM) | ||
| JP2018520993A5 (OSRAM) | ||
| JP2018528776A5 (OSRAM) | ||
| JP2019500862A5 (OSRAM) | ||
| JP2016531907A5 (OSRAM) | ||
| JP2018508215A5 (OSRAM) | ||
| JP2020525533A (ja) | 細胞により発現される生物学的活性を調節する抗体 | |
| JP2019518721A5 (OSRAM) |